Summary:
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Qualified Participants Must:
• Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months
•
HAM-D17 total score of 23 or higher at screening and Baseline
•
Body mass index (BMI) between 18 and 38 kg/m2 (inclusive)
Qualified Participants May Receive:
Monetary compensation for participation.